Optimizing the Route to Regulatory Approval for a Novel Vaccine
The rapid delivery of safe and effective vaccines is critical, clearly demonstrated by COVID-19 pandemic. Streamlining vaccine development through novel trial design is essential for expediting the process. This paper presents key insights on optimizing the path to regulatory approval, with a focus on:
- Early phase studies: To optimize the development of new vaccines, it is crucial to leverage multidisciplinary expertise and include multiple exploratory endpoints. Human challenge studies can be valuable when dealing with mild or treatable infections. Case examples from the literature illustrate the application of these strategies.
- Immune correlates and immuno-bridging: The concepts of immune correlates and immuno-bridging are discussed with example of circumstances when these might be applied in lieu of clinical effectiveness studies.
- Considerations for later phase studies: The challenges associated with clinical effectiveness trials are discussed as well as approaches to accelerate vaccine development such as adaptive trial designs together with examples.
- Generating safety data: The regulatory expectations for safety data are discussed along with examples of known and potential risks to be addressed both pre- and post-approval, including the potential for vaccines to exacerbate subsequent infections
- Population diversity: Addressing population diversity in vaccine development is critical. Factors such as ethnicity, socioeconomic status, nutrition, and gut biota can influence vaccine effectiveness and safety.
Related Insights
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Webinar
Breakthrough Devices Program: Where’s the value?
Nov 13, 2023
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Webinar
EU-CTR: Preparing for trial transition
Nov 30, 2023
Blog
New Infectious Disease, Vaccines Head brings clinical, philanthropic experience
Jun 20, 2023
Related Insights
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Webinar
Breakthrough Devices Program: Where’s the value?
Nov 13, 2023
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Webinar
EU-CTR: Preparing for trial transition
Nov 30, 2023
Blog
New Infectious Disease, Vaccines Head brings clinical, philanthropic experience
Jun 20, 2023